Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 20/20 | 1.00 |
| ▸ | BCR known ✓ | P11274 | 14/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 12/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 1.00 |
| ▸ | ABL2 | P42684 | 7/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 3/20 | 1.00 |
| ▸ | LYN | P07948 | 3/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | SYK | P43405 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | DDX3X | O00571 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 1.00 |
| ▸ | SLC22A3 | O75751 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | CA1 | P00915 | 1/20 | 1.00 |
| ▸ | CA2 | P00918 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imatinib SCHEMBL29351601 | 1.00 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL3827 | 1.00 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL2236091 | 1.00 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL15201213 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL2929858 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL3138052 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL1462774 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL529425 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL1977949 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL16431247 | 0.99 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1050 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739326-A2 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR Biome ApS (DK) | 2026-05-13 | — | — | EP | claimed |
| EP-3850004-B1 | NATURAL KILLER CELL COMPOSITIONS AND IMMUNOTHERAPY METHODS FOR TREATING A LIVER TUMOR | NKARTA INC (US) | 2026-02-18 | — | — | EP | claimed |
| US-20250340837-A1 | CELLS | UNIVERSITY OF GENEVA (CH) | 2025-11-06 | — | — | US | claimed |
| WO-2025129254-A1 | COMPOSITION COMPRISING A CELL PENETRATING, ANTI-DNA BINDING PROTEIN AND METHODS OF TREATMENT | NUCLEUS THERAPEUTICS PTY LTD (AU) | 2025-06-26 | — | — | WO | claimed |
| US-20250188194-A1 | Method of treatment | NUCLEUS THERAPEUTICS PTY LTD (AU) | 2025-06-12 | — | — | US | claimed |
| CN-119816297-A | Parenteral formulation of imatinib | 阿尔托润吉有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119548628-A | Application of GAC as target in enhancing treatment of chronic myelogenous leukemia by imatinib | 广东药科大学 | 2025-03-04 | — | — | CN | claimed |
| EP-4504916-A1 | CELLS | University of Geneva (CH) | 2025-02-12 | — | — | EP | claimed |
| WO-2025008490-A2 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR BIOME APS (DK) | 2025-01-09 | — | — | WO | claimed |
| US-20240377412-A1 | METHODS OF ASSESSING ANTIBODY-DRUG CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2024-11-14 | — | — | US | claimed |
| US-20230158041-A1 | METHODS AND COMPOSITIONS FOR TREATING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-05-25 | — | — | US | claimed |
| WO-2023034778-A1 | METHOD OF TREATMENT | NUCLEUS THERAPEUTICS PTY LTD (AU) | 2023-03-09 | — | — | WO | claimed |
| CN-113521291-B | Application of ZNF143-MDIG-CDC6 axis in hepatocellular carcinoma | 上海市肿瘤研究所 | 2022-11-29 | — | — | CN | claimed |
| CN-111665315-B | Detection and analysis method of anticancer drugs in natural water body | 上海大学 | 2022-11-22 | — | — | CN | claimed |
| US-11369591-B2 | Drug delivery from hydrogels | INCEPT, LLC (US) | 2022-06-28 | — | — | US | claimed |
| CN-108424454-B | Monoclonal antibody 175 targeting EGF receptor, and derivatives and uses thereof | 路德维格癌症研究所有限公司 | 2022-05-31 | — | — | CN | claimed |
| WO-2022101632-A1 | TOUGH, REPROCESSABLE ELASTOMERS AND METHODS OF MAKING AND USING SAME | DUKE UNIVERSITY (US) | 2022-05-19 | — | — | WO | claimed |
| EP-3218007-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER | INST NAT SANTE RECH MED (FR) | 2022-04-06 | — | — | EP | claimed |
| CN-114053275-A | Drug capable of reversing drug resistance of chronic myelogenous leukemia to imatinib drug | 中南大学湘雅医院 | 2022-02-18 | — | — | CN | claimed |
| WO-2022032113-A1 | PHARMACEUTICALS FOR TREATING OR PREVENTING NIDOVIRUSES AND PICORNAVIRUSES | THE UNIVERSITY OF CHICAGO (US) | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158041-A1 | METHODS AND COMPOSITIONS FOR TREATING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE | ABCC3, HTR3A, PKD1 | ABL1 3706/4885BCR 1398/4885KIT 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.